Matej Oresic
Ph.D.
matej.oresic@utu.fi +358 29 450 3798 +358 46 923 3395 Tykistökatu 6 Turku |
Systems biology, exposome, bioinformatics, metabolomics, lipidomics, biophysics, systems medicine, computational biology
Professor Matej Orešič holds a PhD in biophysics from Cornell University (1999; Ithaca, NY, USA). He is professor of medicine, with specialization in systems medicine at Örebro University (Sweden) and a professor of biochemistry (metabolomics) at the University of Turku (Finland). Prof. Orešič’s main research areas include exposomics and metabolomics applications in biomedical research and systems medicine. He is particularly interested in the identification of environmental exposures (exposome) and disease processes associated with different metabolic phenotypes and the underlying mechanisms linking these processes with the development of specific disorders or their co-morbidities. Prof. Orešič also initiated the popular MZmine open-source project, which led to the development and release of popular software for metabolomics data processing. As of 2016, he was made a Lifetime Honorary Fellow of the Metabolomics Society. Professor Orešič currently serves as member of the Board of Directors of the Metabolomics Society and is one of the founders of the Nordic Metabolomics Society, previously serving as its chair of the board. In 2019, he co-chaired the 1st Gordon Research Conference on ‘Metabolomics and Human Health’ (Ventura, CA, USA). Previously, he also chaired the Keystone Symposium on Systems Biology of Lipid Metabolism (2015; Breckenridge, CO, USA). Professor Orešič currently coordinates Horizon Europe project “Inflammation in human early life: targeting impacts on life-course health – INITIALISE (https://initialise-project.eu/)”. He is also Co-Coordinator of the new Horizon Europe project “Investigation of endocrine-disrupting chemicals as contributors to progression of metabolic dysfunction-associated steatotic liver disease – EDC-MASLD (https://edc-masld.eu/)”.
Professor Orešič’s main research areas include exposomics and metabolomics applications in biomedical research and systems medicine. He is particularly interested in the identification of environmental exposures (exposome) and disease processes associated with different metabolic phenotypes and the underlying mechanisms linking these processes with the development of specific disorders or their co-morbidities. Prof. Orešič also initiated the popular MZmine open-source project, which led to the development and release of popular software for metabolomics data processing. Professor Orešič currently coordinates Horizon Europe project “Inflammation in human early life: targeting impacts on life-course health – INITIALISE (https://initialise-project.eu/)”. He is also Co-Coordinator of the new Horizon Europe project “Investigation of endocrine-disrupting chemicals as contributors to progression of metabolic dysfunction-associated steatotic liver disease – EDC-MASLD (https://edc-masld.eu/)”.
- Linking Gut Microbiome and Lipid Metabolism: Moving beyond Associations (2021)
- Metabolites
- Lipidomic Analyses Reveal Modulation of Lipid Metabolism by the PFAS Perfluoroundecanoic Acid (PFUnDA) in Non-Obese Diabetic Mice (2021)
- Frontiers in Genetics
- Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity (2021)
- Metabolites
- Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests (2021)
- Nature Reviews Gastroenterology and Hepatology
- Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue (2021)
- Scandinavian Journal of Gastroenterology
- Quantitative genome-scale metabolic modeling of human CD4+ T cell differentiation reveals subset-specific regulation of glycosphingolipid pathways (2021)
- Cell Reports
- Systems biology approaches to study lipidomes in health and disease (2021)
- Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids
- Technological readiness and implementation of genomic-driven precision medicine for complex diseases (2021)
- Journal of Internal Medicine
- 4β-Hydroxycholesterol Signals From the Liver to Regulate Peripheral Cholesterol Transporters (2020)
- Frontiers in Pharmacology
- Building an international consortium for tracking coronavirus health status (2020)
- Nature Medicine
- Correction: Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state (2020)
- Journal of Biological Chemistry
- Double Derivatization Strategy for High-Sensitivity and High- Coverage Localization of Double Bonds in Free Fatty Acids by Mass Spectrometry (2020)
- Analytical Chemistry
- Early-life exposure to perfluorinated alkyl substances modulates lipid metabolism in progression to celiac disease (2020)
- Environmental Research
- Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease (2020)
- JCI Insight
- Integrative Analysis of Circulating Metabolite Profiles and Magnetic Resonance Imaging Metrics in Patients with Traumatic Brain Injury (2020)
- International Journal of Molecular Sciences
- Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis (2020)
- NPJ Schizophrenia
- MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans (2020)
- Journal of Hepatology
- Metabolic alterations in immune cells associate with progression to type 1 diabetes (2020)
- Diabetologia
- Metabolic Signatures of the Exposome-Quantifying the Impact of Exposure to Environmental Chemicals on Human Health (2020)
- Metabolites
- Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes (2020)
- Environment International